Quidel Corporation (QDEL): Price and Financial Metrics
Quidel Corporation (QDEL)
Today's Latest Price: $227.72 USD
Updated Jan 28 10:39am
Add QDEL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
QDEL Stock Summary
- Price to trailing twelve month operating cash flow for QDEL is currently 39.57, higher than 88.08% of US stocks with positive operating cash flow.
- Over the past twelve months, QDEL has reported earnings growth of 454.14%, putting it ahead of 96.75% of US stocks in our set.
- Revenue growth over the past 12 months for Quidel Corp comes in at 94.96%, a number that bests 94.49% of the US stocks we're tracking.
- Stocks that are quantitatively similar to QDEL, based on their financial statements, market capitalization, and price volatility, are IRBT, NATI, FLIR, MKSI, and ATHM.
- QDEL's SEC filings can be seen here. And to visit Quidel Corp's official web site, go to www.quidel.com.
QDEL Stock Price Chart Interactive Chart >
QDEL Price/Volume Stats
| Current price | $227.72 | 52-week high | $306.72 |
| Prev. close | $224.21 | 52-week low | $72.99 |
| Day low | $221.71 | Volume | 92,832 |
| Day high | $229.99 | Avg. volume | 1,056,543 |
| 50-day MA | $198.48 | Dividend yield | N/A |
| 200-day MA | $206.47 | Market Cap | 9.58B |
Quidel Corporation (QDEL) Company Bio
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $227.72 | $148.04 | -34% |
Below please find a table outlining a discounted cash flow forecast for QDEL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quidel Corp ranked in the 41th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Quidel Corp, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 44.05; that's higher than 91.42% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.15% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 51.49% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -35% |
| 1% | -35% |
| 2% | -34% |
| 3% | -33% |
| 4% | -33% |
| 5% | -32% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as QDEL, try STE, MEDP, AMGN, INBP, and NVS.
Loading social stream, please wait...